ES2062330T3 - Conjugados. - Google Patents

Conjugados.

Info

Publication number
ES2062330T3
ES2062330T3 ES90301589T ES90301589T ES2062330T3 ES 2062330 T3 ES2062330 T3 ES 2062330T3 ES 90301589 T ES90301589 T ES 90301589T ES 90301589 T ES90301589 T ES 90301589T ES 2062330 T3 ES2062330 T3 ES 2062330T3
Authority
ES
Spain
Prior art keywords
hbcag
lys
polypeptide
particles
conjugates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90301589T
Other languages
English (en)
Inventor
David John Rowlands
Berwyn Ewart Clarke
Michael James Francis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellcome Foundation Ltd
Original Assignee
Wellcome Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellcome Foundation Ltd filed Critical Wellcome Foundation Ltd
Application granted granted Critical
Publication of ES2062330T3 publication Critical patent/ES2062330T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

PARTICULAS (HBCAG) ANTIGENAS DEL NUCLEO DE LA HEPATITIS B, QUE LLEVAN UN POLIPEPTIDO QUE PRESENTA UN EPITOPO ANTIGENICO Y QUE SON ADECUADAS PARA USO EN VACUNAS, SE COMPONE DE HBCAG PROVISTO CON UNA EXTENSION TERMINAL N QUE INCORPORA UN RESIDUO "LYS" Y EL MENCIONADO POLIPEPTIDO SE ACOPLA A LAS PARTICULAS POR MEDIO DEL GRUPO AMINO DE CADENA LATERAL DEL RESIDUO "LYS".
ES90301589T 1989-02-14 1990-02-14 Conjugados. Expired - Lifetime ES2062330T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB898903313A GB8903313D0 (en) 1989-02-14 1989-02-14 Conjugates

Publications (1)

Publication Number Publication Date
ES2062330T3 true ES2062330T3 (es) 1994-12-16

Family

ID=10651663

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90301589T Expired - Lifetime ES2062330T3 (es) 1989-02-14 1990-02-14 Conjugados.

Country Status (11)

Country Link
EP (1) EP0385610B1 (es)
JP (1) JP2858848B2 (es)
AU (1) AU634518B2 (es)
CA (1) CA2009896A1 (es)
DE (1) DE69007311T2 (es)
DK (1) DK0385610T3 (es)
ES (1) ES2062330T3 (es)
GB (1) GB8903313D0 (es)
IE (1) IE64983B1 (es)
NZ (1) NZ232505A (es)
ZA (1) ZA901086B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0300213A1 (en) * 1987-06-22 1989-01-25 Hexal-Pharma Gentechnik GmbH & Co. KG Hepatitis a viral peptide particle immunogens
EP0491077A1 (en) * 1990-12-19 1992-06-24 Medeva Holdings B.V. A composition used as a therapeutic agent against chronic viral hepatic diseases
EP0563091A1 (en) * 1990-12-20 1993-10-06 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccines based on hepatitis b surface antigen
US5607691A (en) * 1992-06-12 1997-03-04 Affymax Technologies N.V. Compositions and methods for enhanced drug delivery
FR2699538B1 (fr) * 1992-12-22 1995-02-03 Agronomique Inst Nat Rech Sous-unité d'une capsule protéique CS31A modifiée par au moins un peptide hétérologue, capsule protéique CS31A et microorganismes portant ces sous-unités; procédés d'obtention et utilisation de ceux-ci.
AU2540897A (en) * 1996-03-21 1997-10-10 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Methods and compositions of chimeric polypeptides for tumor antigen vaccines
CZ302092B6 (cs) * 1998-02-12 2010-10-06 Immune Complex, Corporation Konjugát upraveného jaderného proteinu hepatitidy B, jeho cástice, inokulum a zpusob indukce protilátek
DE69929232T2 (de) 1998-10-21 2006-08-31 The United States Government As Represented By The Department Of Health And Human Services Virusähnliche partikel zur induktion von autoantikörpern
MXPA01005389A (es) * 1998-11-30 2003-03-27 Cytos Biotechnology Ag Presentacion molecular ordenada de antigenos, metodos de preparacion y uso.
TR200102423T2 (tr) 1998-12-04 2002-02-21 Biogen, Inc. Peptid ligandları yoluyla bağlı birden fazla imünojenik bileşeni olan HBV çekirdek antijeni parçacıkları
CA2407897A1 (en) 2000-05-05 2001-11-15 Cytos Biotechnology Ag Molecular antigen arrays and vaccines
US7264810B2 (en) 2001-01-19 2007-09-04 Cytos Biotechnology Ag Molecular antigen array
US7128911B2 (en) 2001-01-19 2006-10-31 Cytos Biotechnology Ag Antigen arrays for treatment of bone disease
US7094409B2 (en) 2001-01-19 2006-08-22 Cytos Biotechnology Ag Antigen arrays for treatment of allergic eosinophilic diseases
US7115266B2 (en) 2001-10-05 2006-10-03 Cytos Biotechnology Ag Angiotensin peptide-carrier conjugates and uses thereof
US7138252B2 (en) 2002-07-17 2006-11-21 Cytos Biotechnology Ag Molecular antigen arrays
CA2487849A1 (en) 2002-07-18 2004-01-29 Cytos Biotechnology Ag Hapten-carrier conjugates comprising virus like particles and uses thereof
EP2338510A1 (en) 2002-07-19 2011-06-29 Novartis Pharma AG Vaccine compositions containing amyloid beta1-6 antigen arrays
AU2004224761A1 (en) 2003-03-26 2004-10-07 Cytos Biotechnology Ag HIV-peptide-carrier-conjugates
US7537767B2 (en) 2003-03-26 2009-05-26 Cytis Biotechnology Ag Melan-A- carrier conjugates
US8080642B2 (en) 2003-05-16 2011-12-20 Vical Incorporated Severe acute respiratory syndrome DNA compositions and methods of use
JP5331340B2 (ja) 2004-05-18 2013-10-30 バイカル インコーポレイテッド インフルエンザウィルスワクチン組成物、及びその使用方法
GB0424563D0 (en) 2004-11-05 2004-12-08 Novartis Ag Organic compounds
US10279028B2 (en) 2012-04-24 2019-05-07 Ohio State Innovation Foundation Compositions and methods for treating and preventing porcine reproductive and respiratory syndrome
CA2871786C (en) 2012-04-24 2021-11-16 Ohio State Innovation Foundation Compositions and methods for treating and preventing porcine reproductive and respiratory syndrome

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8421282D0 (en) * 1984-08-22 1984-09-26 Connaught Lab Multispecific antigenic proteins
US4882145A (en) * 1986-12-09 1989-11-21 Scripps Clinic And Research Foundation T cell epitopes of the hepatitis B virus nucleocapsid protein
GB8709274D0 (en) * 1987-04-16 1987-05-20 Wellcome Found Peptides

Also Published As

Publication number Publication date
IE64983B1 (en) 1995-09-20
IE900502L (en) 1990-08-14
NZ232505A (en) 1992-12-23
DE69007311T2 (de) 1994-06-23
EP0385610B1 (en) 1994-03-16
AU634518B2 (en) 1993-02-25
ZA901086B (en) 1990-11-28
JPH0327400A (ja) 1991-02-05
GB8903313D0 (en) 1989-04-05
DE69007311D1 (de) 1994-04-21
JP2858848B2 (ja) 1999-02-17
CA2009896A1 (en) 1990-08-14
DK0385610T3 (da) 1994-07-25
EP0385610A1 (en) 1990-09-05
AU4975590A (en) 1990-10-18

Similar Documents

Publication Publication Date Title
ES2062330T3 (es) Conjugados.
ES2075440T3 (es) Vacuna contra la hepatitis b.
ES2138784T3 (es) Antigenos sinteticos para la deteccion de anticuerpos contra el virus de la hepatitis c.
GB2255093A (en) Hiv-1 core protein fragments
ES2081102T3 (es) Vacuna para el herpes simple compuesta por glicoproteina gd del hsv y lipido a de monofosforilo 3-desacilado.
CY1108299T1 (el) Πεπτιδια του ιου ανθρωπινης ανοσοανεπαρκειας (hiv), αντιγονα και συνθεσεις εμβολιου
ATE496630T1 (de) Immunologische zusammensetzung und impfstoffe, die einen auf n-formyl-methionyl peptide bestehenden adjuvans enthalten
NZ219113A (en) Hiv peptide containing epitope of the env protein
CY1107706T1 (el) Πεπτιδια ανταγωνιστες καρκινοεμβρυονικου αντιγονου (cea)
AR004464A1 (es) Un metodo para producir una proteina de capside de papilomavirus
ATE90388T1 (de) Schuetzendes peptid-antigen.
ES8608883A1 (es) Procedimiento de preparacion de un conjugado de muramilpeptido y de un hapteno o fragmento haptenico de bajo peso molecular.
ES2137160T3 (es) Lipopeptidos inductores de los linfocitos t-citotoxicos y utilizacion como vacunas.
EP0317804A3 (en) Hiv peptides and methods for detection of hiv
IT1254360B (it) Epitopi immunologicamente omologhi di hla e proteine del virus hiv.
GB2250994B (en) Peptide fragments of hiv
AR009365A1 (es) Vacunas del virus de la fiebre aftosa (fmdv), peptidos, secuencias de adn y el uso de los peptidos en sistemas de deteccion y el uso de la vacuna fmdc para la preparacion de una composicion para inmunizar cerdos y ganado vacuno
IT1249684B (it) Epitopi della proteina env del virus dell'epatite c.
ATE72400T1 (de) Kreuzreaktive und schuetzende epitope von circumsporozoit-proteinen.
OA09653A (en) Rubella peptides
ES2005753A6 (es) Procedimiento para la preparacion de polipeptidos inmunologicamente activos utiles para la obtencion de vacunas antimalaria y para la deteccion de enfermedades paludicas.
EP0314240A3 (en) Process for purifying recombinant hepatitis antigens
MX9102647A (es) Nueva proteina capaz de inducir una respuesta inmunoprotectora contra la infeccion causada por toxoplasma gondii y para clonar y expresar un gen que codifica a la proteina.
NO881661L (no) Humane rhinoviruspeptider.
ES2037795T3 (es) Procedimiento para la preparacion del antigeno hrpii de plasmodium falciparum sge2.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 385610

Country of ref document: ES